Groundbreaking Patent Granted to Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) has recently made a significant leap forward in the biopharmaceutical arena with the granting of a new patent. This Canadian patent, known as number 3,174,137, is crucial for the composition of PALI-2108, a leading candidate in their pipeline targeting fibrostenotic Crohn’s disease and ulcerative colitis. PALI-2108 is unique as the first PDE4 inhibitor crafted specifically for effective targeting of the terminal ileum and colon.
Understanding PALI-2108 and Its Mechanism
PALI-2108 stands out for its innovative design and approach. It is an orally administered drug that serves as a prodrug, meaning it becomes active only after being metabolized in the gut. This allows it to deliver potent anti-inflammatory effects directly to the site, reducing the unwelcome systemic side effects often associated with other treatments. The unique composition of PALI-2108 includes a sugar moiety derived from galactose, which helps it achieve localized bioactivation through the bacterial enzyme ?-glucuronidase, ensuring a targeted release in the colon.
Palisade Bio's Commitment to Development
CEO J.D. Finley emphasized the company's dedication to the development of PALI-2108, stating their focus on enhancing the intellectual property surrounding this pioneering product. The addition of this patent is a strategic move that strengthens Palisade's position and enhances its overall portfolio in the competitive biopharmaceutical landscape.
Clinical Trials and Future Prospects
As of now, Palisade Bio is in the midst of its Phase 1b clinical study for PALI-2108, targeting patients suffering from fibrostenotic Crohn’s disease with expected dosing to commence in the later half of the upcoming year. The results of this trial are highly anticipated, as they will not only provide valuable insights but also pave the way for further regulatory submissions to the U.S. Food and Drug Administration (FDA) in the first half of the subsequent year.
The Importance of Clinical Data
Data gathered from the earlier Phase 1a/1b trials focused on ulcerative colitis will be incredibly important for this upcoming IND submission. The ability to demonstrate safety and efficacy through robust clinical data will play a pivotal role in advancing PALI-2108 through the regulatory pathways while illustrating its therapeutic potential to address significant unmet medical needs in these challenging conditions.
About Palisade Bio's Vision
Palisade Bio is committed to transforming the treatment landscape for autoimmune, inflammatory, and fibrotic diseases. The focus on developing innovative therapeutics using a targeted approach differs from traditional methods, aiming to improve patient outcomes and quality of life significantly.
Long-Term Impact on Patients
With a unique mechanism that targets gut delivery, PALI-2108 could revolutionize how patients experience treatment for Crohn’s disease and ulcerative colitis. By minimizing systemic absorption and concentrating the therapeutic effect directly where it's needed, patients may suffer fewer side effects, thus improving adherence to treatment regimens.
Investor Engagement and Future Communication
For those interested in the impressive developments at Palisade Bio, the company actively engages with its investor community through regular updates and public communications. Interested parties can get more information regarding ongoing projects and clinical progress by visiting the company's official website and reaching out directly to their investor relations contact, Jenene Thomas.
Frequently Asked Questions
What is PALI-2108?
PALI-2108 is an innovative orally administered prodrug designed to target the terminal ileum and colon, specifically for treating fibrostenotic Crohn's disease and ulcerative colitis.
How does the new patent impact Palisade Bio?
The granted patent secures composition-of-matter protection for PALI-2108, bolstering Palisade Bio's intellectual property portfolio and enhancing its strategic position in the market.
What are the next steps for PALI-2108?
The next steps include conducting further clinical trials, with patient dosing for Phase 1b anticipated to begin soon, followed by data analysis and potential FDA submissions.
Why is local activation of PALI-2108 significant?
Local activation minimizes systemic exposure, which can lead to reduced side effects and enhance the therapeutic effects specifically where they are needed in the gastrointestinal tract.
How can investors learn more about Palisade Bio?
Investors can stay updated on developments by visiting Palisade Bio's official website or contacting their investor relations team for recent updates.
